ATLANTA--(BUSINESS WIRE)--Galt Pharmaceuticals announced the acquisition of a specialty branded product from Fortovia Therapeutics. Effective December 2, 2020, Galt added Oravig®, the first and only orally-dissolving buccal tablet for oral thrush, to its growing portfolio of pharmaceutical assets.
m8 Pharmaceuticals and Vectans Pharma, announced they have signed an exclusive licensing agreement whereby m8 will have the rights to register and commercialize Loramyc® (miconazole) for Mexico and Brazil. Loramyc® is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. Vectans received its first Loramyc® marketing authorization in France in October 2006. Loramyc® has since been registered in 26 European countries, in South Korea, Japan and in the United States amongst others.
The TGA would like to thank the respondents who have submitted written comments or made submissions in response to the consultation: miconazole and fluconazole: proposed advisory statements for medicines.
SAN ANTONIO, TX (October 27, 2015) — With the DARA BioSciences, Inc. (Nasdaq: DARA) announcement of the U.S. launch of Oravig® (miconazole), the first and only orally- dissolving muco-adhesive buccal tablet approved to treat adults with oral thrush, Mission Pharmacal Company has further demonstrated its unique partnering strategy to help patients obtain needed medication.
Two Existing Drugs May Reverse Damage Caused By Multiple Sclerosis
Could a Non-Prescription Antifungal Become a Major Advance for Multiple Sclerosis?